Literature DB >> 7561063

Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.

L A Cavacini1, C L Emes, J Power, F D Desharnais, M Duval, D Montefiori, M R Posner.   

Abstract

F105, a neutralizing IgG1 kappa human mAb, is reactive with a discontinuous epitope within the gp120 CD4 binding site. Because isotype usage may affect Ab function, we examined the effect of isotype on Ag/Ab interactions and HIV-1 neutralization. An IgG3 kappa Ab was prepared by linking the variable regions of F105 to cloned human kappa and gamma 3 constant regions. Immunoreactivity of F105 IgG1 and IgG3 with IIIB-, MN-, and RF-infected cells was equivalent. Inhibition of binding and fusion of IIIB to uninfected cells and neutralization of IIIB virus was comparable for F105 IgG1 and IgG3, with 14 to 23 micrograms/ml required for 90% neutralization. In contrast, F105 IgG3 was marginally more effective at inhibition of MN binding/fusion and significantly more effective at neutralization of MN virus (62 micrograms/ml for IgG3 and > 100 micrograms/ml for IgG1 to achieve 90% neutralization). Despite high affinity binding to RF-infected cells, F105 IgG1 minimally neutralizes free RF virus. F105 IgG3 is dramatically more effective against the RF isolate, with 2 to 20 micrograms/ml of Ab required for 50% neutralization. Both isotypes were relatively ineffective at inhibition of RF binding/fusion. Thus, whereas affinity with native Ags on the surface of HIV-1-infected cells was unaffected by heavy chain constant regions, Ab isotype can strongly influence virion neutralization. Structural changes in gp120, as a result of increased flexibility conferred by the elongated IgG3 hinge region, are suggested as a possible mechanism to increase neutralization of selected HIV-1 isolates. These results may have significant implications in the design of immunotherapeutic and vaccine agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561063

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.

Authors:  F C Verrier; P Charneau; R Altmeyer; S Laurent; A M Borman; M Girard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

4.  Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Authors:  O Scharf; H Golding; L R King; N Eller; D Frazier; B Golding; D E Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

6.  Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

Authors:  Susanne Wolbank; Renate Kunert; Gabriela Stiegler; Hermann Katinger
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).

Authors:  Rosina Plomp; Gillian Dekkers; Yoann Rombouts; Remco Visser; Carolien A M Koeleman; Guinevere S M Kammeijer; Bas C Jansen; Theo Rispens; Paul J Hensbergen; Gestur Vidarsson; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2015-03-10       Impact factor: 5.911

8.  Early development of broadly neutralizing antibodies in HIV-1-infected infants.

Authors:  Leslie Goo; Vrasha Chohan; Ruth Nduati; Julie Overbaugh
Journal:  Nat Med       Date:  2014-05-25       Impact factor: 53.440

9.  Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Authors:  Fausto Titti; Maria T Maggiorella; Flavia Ferrantelli; Leonardo Sernicola; Stefania Bellino; Barbara Collacchi; Emanuele Fanales Belasio; Sonia Moretti; Maria Rosaria Pavone Cossut; Roberto Belli; Erika Olivieri; Stefania Farcomeni; Daniela Compagnoni; Zuleika Michelini; Michela Sabbatucci; Katia Sparnacci; Luisa Tondelli; Michele Laus; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

10.  Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells.

Authors:  Yun S Goh; Andrew J Grant; Olivier Restif; Trevelyan J McKinley; Kathryn L Armour; Michael R Clark; Pietro Mastroeni
Journal:  Immunology       Date:  2011-02-16       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.